vs
Side-by-side financial comparison of IPG PHOTONICS CORP (IPGP) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
IPG PHOTONICS CORP is the larger business by last-quarter revenue ($274.5M vs $196.9M, roughly 1.4× Pacira BioSciences, Inc.). On growth, IPG PHOTONICS CORP posted the faster year-over-year revenue change (17.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $10.9M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 4.4%).
IPG Photonics Corporation is a manufacturer of fiber lasers. IPG Photonics developed and commercialized optical fiber lasers, which are used in a variety of applications including materials processing, medical applications and telecommunications. IPG has manufacturing facilities in the United States, Germany, Russia and Italy.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IPGP vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $274.5M | $196.9M |
| Net Profit | $13.3M | — |
| Gross Margin | 36.1% | 79.5% |
| Operating Margin | 1.2% | 1.2% |
| Net Margin | 4.8% | — |
| Revenue YoY | 17.1% | 5.1% |
| Net Profit YoY | 69.8% | — |
| EPS (diluted) | $0.30 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $274.5M | $196.9M | ||
| Q3 25 | $250.8M | $179.5M | ||
| Q2 25 | $250.7M | $181.1M | ||
| Q1 25 | $227.8M | $168.9M | ||
| Q4 24 | $234.3M | $187.3M | ||
| Q3 24 | $233.1M | $168.6M | ||
| Q2 24 | $257.6M | $178.0M | ||
| Q1 24 | $252.0M | $167.1M |
| Q4 25 | $13.3M | — | ||
| Q3 25 | $7.5M | $5.4M | ||
| Q2 25 | $6.6M | $-4.8M | ||
| Q1 25 | $3.8M | $4.8M | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $-233.6M | $-143.5M | ||
| Q2 24 | $20.2M | $18.9M | ||
| Q1 24 | $24.1M | $9.0M |
| Q4 25 | 36.1% | 79.5% | ||
| Q3 25 | 39.5% | 80.9% | ||
| Q2 25 | 37.3% | 77.4% | ||
| Q1 25 | 39.4% | 79.7% | ||
| Q4 24 | 38.6% | 78.7% | ||
| Q3 24 | 23.2% | 76.9% | ||
| Q2 24 | 37.3% | 75.1% | ||
| Q1 24 | 38.7% | 71.6% |
| Q4 25 | 1.2% | 1.2% | ||
| Q3 25 | 3.1% | 3.5% | ||
| Q2 25 | 0.0% | 4.7% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 6.0% | 13.2% | ||
| Q3 24 | -108.7% | -82.8% | ||
| Q2 24 | 4.7% | 15.9% | ||
| Q1 24 | 7.6% | 7.9% |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 3.0% | 3.0% | ||
| Q2 25 | 2.6% | -2.7% | ||
| Q1 25 | 1.6% | 2.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -100.2% | -85.1% | ||
| Q2 24 | 7.8% | 10.6% | ||
| Q1 24 | 9.6% | 5.4% |
| Q4 25 | $0.30 | $0.05 | ||
| Q3 25 | $0.18 | $0.12 | ||
| Q2 25 | $0.16 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $0.27 | $0.38 | ||
| Q3 24 | $-5.33 | $-3.11 | ||
| Q2 24 | $0.45 | $0.39 | ||
| Q1 24 | $0.52 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $839.3M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $2.1B | $693.1M |
| Total Assets | $2.4B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $839.3M | $238.4M | ||
| Q3 25 | $870.4M | $246.3M | ||
| Q2 25 | $899.6M | $445.9M | ||
| Q1 25 | $926.9M | $493.6M | ||
| Q4 24 | $930.2M | $484.6M | ||
| Q3 24 | $1.0B | $453.8M | ||
| Q2 24 | $1.1B | $404.2M | ||
| Q1 24 | $1.1B | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.1B | $693.1M | ||
| Q3 25 | $2.1B | $727.2M | ||
| Q2 25 | $2.1B | $757.8M | ||
| Q1 25 | $2.1B | $798.5M | ||
| Q4 24 | $2.0B | $778.3M | ||
| Q3 24 | $2.1B | $749.6M | ||
| Q2 24 | $2.3B | $879.3M | ||
| Q1 24 | $2.3B | $892.2M |
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.4B | $1.5B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.3B | $1.6B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B | ||
| Q1 24 | $2.6B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.8M | $43.7M |
| Free Cash FlowOCF − Capex | $10.9M | $43.5M |
| FCF MarginFCF / Revenue | 4.0% | 22.1% |
| Capex IntensityCapex / Revenue | 6.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.5M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.8M | $43.7M | ||
| Q3 25 | $35.3M | $60.8M | ||
| Q2 25 | $-2.2M | $12.0M | ||
| Q1 25 | $13.4M | $35.5M | ||
| Q4 24 | $73.8M | $33.1M | ||
| Q3 24 | $66.1M | $53.9M | ||
| Q2 24 | $53.5M | $53.2M | ||
| Q1 24 | $54.6M | $49.1M |
| Q4 25 | $10.9M | $43.5M | ||
| Q3 25 | $14.6M | $57.0M | ||
| Q2 25 | $-17.6M | $9.3M | ||
| Q1 25 | $-11.4M | $26.9M | ||
| Q4 24 | $50.6M | $31.0M | ||
| Q3 24 | $43.0M | $49.8M | ||
| Q2 24 | $29.2M | $51.6M | ||
| Q1 24 | $26.5M | $46.3M |
| Q4 25 | 4.0% | 22.1% | ||
| Q3 25 | 5.8% | 31.7% | ||
| Q2 25 | -7.0% | 5.1% | ||
| Q1 25 | -5.0% | 15.9% | ||
| Q4 24 | 21.6% | 16.6% | ||
| Q3 24 | 18.4% | 29.6% | ||
| Q2 24 | 11.3% | 29.0% | ||
| Q1 24 | 10.5% | 27.7% |
| Q4 25 | 6.5% | 0.1% | ||
| Q3 25 | 8.3% | 2.2% | ||
| Q2 25 | 6.1% | 1.5% | ||
| Q1 25 | 10.9% | 5.1% | ||
| Q4 24 | 9.9% | 1.1% | ||
| Q3 24 | 9.9% | 2.4% | ||
| Q2 24 | 9.4% | 0.9% | ||
| Q1 24 | 11.1% | 1.7% |
| Q4 25 | 2.17× | — | ||
| Q3 25 | 4.73× | 11.20× | ||
| Q2 25 | -0.34× | — | ||
| Q1 25 | 3.58× | 7.37× | ||
| Q4 24 | 9.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.65× | 2.82× | ||
| Q1 24 | 2.27× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IPGP
| Materials Processing | $232.8M | 85% |
| Laser And Non Laser Systems | $38.8M | 14% |
| Transferred Over Time | $5.3M | 2% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
